Analyst Ratings January 28, 2026

Guggenheim Lifts Sysco Price Target to $91, Citing Management’s Near-Term Improvement Plan

Analysts raise targets after strong quarter and a one-day stock surge tied to management commentary on self-help actions

By Priya Menon SYY
Guggenheim Lifts Sysco Price Target to $91, Citing Management’s Near-Term Improvement Plan
SYY

Guggenheim increased its price objective for Sysco to $91 from $89 and kept a Buy rating after a sharp share rally and management guidance around top- and bottom-line improvements. The firm’s valuation relies on an 11.0x EBITDA multiple on 2027 results and assumes an 11% total shareholder return including dividends. Other major brokerages also nudged targets higher following Sysco’s fiscal Q2 2026 results that slightly beat estimates.

Key Points

  • Guggenheim raised its Sysco price target to $91 from $89 and kept a Buy rating, assuming an 11.0x EBITDA multiple on 2027 results.
  • The stock surged 11% in a single day - its largest one-day gain since 2020 - and has returned 19.36% over the past year.
  • Other brokers (UBS, Bernstein, Piper Sandler) also raised targets after Sysco beat Q2 fiscal 2026 EPS and revenue expectations and reported improving U.S. local case volumes.

Guggenheim has raised its price target on Sysco (NYSE: SYY) to $91.00 from $89.00 while maintaining a Buy rating, reflecting what the firm described as growing confidence in the company’s ability to execute near-term improvement initiatives. The new target implies additional upside from recent trading levels - Sysco shares were at $84.14 at the time of the update and have produced a 19.36% return over the past 12 months.

The upgrade from Guggenheim followed an 11% jump in Sysco’s stock on Tuesday, a single-day gain the firm said was the company’s largest since 2020. That move materially outpaced the S&P 500’s 0.4% advance on the same day.

Guggenheim attributed the rapid share-price appreciation to management’s upbeat comments about progress on self-help measures and a clear commitment to specified top- and bottom-line improvements over the coming six months. The shop noted that while the targets management set do not appear overly aggressive, meeting them is critical to sustain the current valuation.

The new $91 target is based on an assumed 11.0x EBITDA multiple applied to Sysco’s 2027 results. Guggenheim observed that this multiple sits at the upper end of the 9-12x range it cites for foodservice distributors, and the target equates to an estimated 11% total shareholder return when dividends are included.

Sysco’s recently reported second-quarter results for fiscal 2026 provided the backdrop for the analyst interest. The company posted EPS of $0.99, narrowly above the $0.98 consensus, and reported total revenue of $21.0 billion versus forecasts of $20.78 billion.

Following the quarterly report, other brokerages also revised their valuations. UBS lifted its Sysco price target to $95 and kept a Buy rating, pointing to stronger U.S. local case volumes that improved by 140 basis points sequentially to 1.2%. Bernstein raised its target to $90, highlighting robust top-line performance and noting that local case volume growth in U.S. Foodservice exceeded its own expectations. Piper Sandler moved its target to $83, similarly citing positive case growth with local U.S. Foodservice case growth of 1.2%.

Together, the analyst moves reflect a broadly favorable response to Sysco’s recent operating results and management commentary. However, the various price-target changes are predicated on continued performance consistent with management’s stated objectives and the volume improvements reported in U.S. Foodservice.


Summary

  • Guggenheim raised its price target on Sysco to $91 from $89 and retained a Buy rating.
  • The stock rallied 11% in one day - its strongest single-day gain since 2020 - and traded at $84.14 while up 19.36% over the past year.
  • Analyst targets from UBS, Bernstein, and Piper Sandler were also increased after Sysco slightly beat EPS and revenue expectations for fiscal Q2 2026 and reported improved U.S. local case volumes.

Key points

  • Valuation assumption - Guggenheim’s $91 target uses an 11.0x EBITDA multiple on 2027 results, near the top of the 9-12x range typical for foodservice distributors.
  • Near-term execution - Management’s commitment to deliver measurable top- and bottom-line improvements over the next six months is central to justifying current valuations.
  • Sectors impacted - Moves affect foodservice distribution and related U.S. Foodservice segments, as well as investor sentiment in equities for distributors and broader market participation.

Risks and uncertainties

  • Execution risk - Guggenheim stressed that management targets are not aggressive but must be achieved to support the valuation; failure to deliver would challenge the current price assumptions. This risk primarily affects the foodservice distribution sector.
  • Volume dependency - Analyst optimism is tied to improvements in U.S. local case volumes; if those trends reverse or disappoint, outlooks and price targets could be undermined. This uncertainty impacts U.S. Foodservice operators and distributors.
  • Valuation sensitivity - The new target assumes an 11.0x EBITDA multiple on 2027 results; reliance on a higher-end multiple means valuation is sensitive to both operating results and multiple compression in the market.

Risks

  • Management must deliver stated top- and bottom-line improvements over the next six months to justify current valuations - failure to do so would undermine price targets.
  • Analyst optimism is tied to U.S. local case volume improvements; any reversal in volume trends would put pressure on outlooks for U.S. Foodservice and distributors.
  • Price targets rely on a relatively high EBITDA multiple assumption (11.0x for 2027) which makes valuations sensitive to multiple compression or weaker-than-expected results.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026